A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease

Autor: Annie Latif, Arunima Mukhopadhyay, Mhairi Copland, Fiona Thomson, Dragana Milojkovic, Letizia Foroni, G. M. Smith, Jenny Byrne, Gillian A. Horne, Paolo Gallipoli, Philippe Schafhausen, Judith Dixon-Hughes, Franck E. Nicolini, P. Cony-Makhoul, Richard E. Clark, Wenjuan Cong, Gudmundur Vignir Helgason, Jon Stobo, Steffen Koschmieder, T H Brümmendorf, Lynn McMahon, Caroline Kelly, Tessa L. Holyoake

Publikováno v: Leukemia
LEUKEMIA
Horne, G, Stobo, J, Kelly, C, Mukhopadhyay, A, Latif, A, Dixon, J, McMahon, L, Cony-Makhoul, P, Byrne, J, Smith, G, Koschmieder, S, BrÜmmendorf, T, Schafhausen, P, Gallipoli, P, Thomson, F, Cong, W, Clark, R, Milojkovic, D, Helgason, V, Foroni, L, NICOLINI, F-E, Holyoake, T & Copland, M 2020, ' A randomised Phase II trial of Hydroxychloroquine and Imatinib versus Imatinib alone for patients with Chronic Myeloid Leukaemia in Major Cytogenetic Response with residual disease ', Leukemia . https://doi.org/10.1038/s41375-019-0700-9

1 In chronic-phase chronic myeloid leukaemia (CP-CML), residual BCR-ABL1+ leukaemia stem cells are 2 responsible for disease persistence despite TKI. Based on in vitro data, CHOICES (CHlorOquine and 3 Imatinib Combination to Eliminate Stem cells) was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24af8c15119e8a2c9bc14fffc509365b
http://europepmc.org/articles/PMC7224085

Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure–response analysis of a Phase III study

Autor: Xiaoning Wang, Amit Roy, Andreas Hochhaus, Tai-Tsang Chen, Hagop M. Kantarjian, Neil P. Shah

Publikováno v: Clinical Pharmacology : Advances and Applications
Clinical pharmacology : advances and applications, vol 5, iss 1

Xiaoning Wang,1 Amit Roy,2 Andreas Hochhaus,3 Hagop M Kantarjian,4 Tai-Tsang Chen,5 Neil P Shah6 1Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb, Lawrenceville, NJ, USA; 2Clinical Pharmacology and Pharmacometrics, Research and Dev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58cb536563b034b40e81bd17a90813b0
https://www.dovepress.com/differential-effects-of-dosing-regimen-on-the-safety-and-efficacy-of-d-peer-reviewed-article-CPAA

Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion Myelodysplastic Syndrome Treated with Lenalidomide

Autor: Bagi Jana, Anas Khanfar, Mary Ninan

Publikováno v: Case Reports in Oncological Medicine
Case Reports in Oncological Medicine, Vol 2014 (2014)

Myelodysplastic syndrome (MDS) is a clonal bone marrow disorder characterized by ineffective hematopoiesis. It is characterized by peripheral blood cytopenia and significant risk of progression to acute myeloid leukemia result. Deletion of the long a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34251aae7cbfd6779e50db93b49b325a
http://europepmc.org/articles/PMC3970358

Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia

Autor: Johannes Kahrs, Tobias Gedde Dahl, Waleed Ghanima, Geir E. Tjønnfjord

Publikováno v: European Journal of Haematology. 72:441-443

A 58-yr-old woman was diagnosed with Ph(+) chronic myeloid leukaemia in May 2001. She was initially treated with hydroxyurea and subsequently with interferon-alpha (IFN-alpha). Imatinib mesylate was started in April 2002 after failure of IFN-alpha to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c07639fdf1ac5670d0b62535f0f2ce51
https://doi.org/10.1111/j.1600-0609.2004.00257.x

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.